Comparison of antiviral activity between IgA and IgG specific to influenza virus hemagglutinin: increased potential of IgA for heterosubtypic immunity
- PMID: 24465606
- PMCID: PMC3895000
- DOI: 10.1371/journal.pone.0085582
Comparison of antiviral activity between IgA and IgG specific to influenza virus hemagglutinin: increased potential of IgA for heterosubtypic immunity
Abstract
Both IgA and IgG antibodies are known to play important roles in protection against influenza virus infection. While IgG is the major isotype induced systemically, IgA is predominant in mucosal tissues, including the upper respiratory tract. Although IgA antibodies are believed to have unique advantages in mucosal immunity, information on direct comparisons of the in vitro antiviral activities of IgA and IgG antibodies recognizing the same epitope is limited. In this study, we demonstrate differences in antiviral activities between these isotypes using monoclonal IgA and IgG antibodies obtained from hybridomas of the same origin. Polymeric IgA-producing hybridoma cells were successfully subcloned from those originally producing monoclonal antibody S139/1, a hemaggulutinin (HA)-specific IgG that was generated against an influenza A virus strain of the H3 subtype but had cross-neutralizing activities against the H1, H2, H13, and H16 subtypes. These monoclonal S139/1 IgA and IgG antibodies were assumed to recognize the same epitope and thus used to compare their antiviral activities. We found that both S139/1 IgA and IgG antibodies strongly bound to the homologous H3 virus in an enzyme-linked immunosorbent assay, and there were no significant differences in their hemagglutination-inhibiting and neutralizing activities against the H3 virus. In contrast, S139/1 IgA showed remarkably higher cross-binding to and antiviral activities against H1, H2, and H13 viruses than S139/1 IgG. It was also noted that S139/1 IgA, but not IgG, drastically suppressed the extracellular release of the viruses from infected cells. Electron microscopy revealed that S139/1 IgA deposited newly produced viral particles on the cell surface, most likely by tethering the particles. These results suggest that anti-HA IgA has greater potential to prevent influenza A virus infection than IgG antibodies, likely due to increased avidity conferred by its multivalency, and that this advantage may be particularly important for heterosubtypic immunity.
Conflict of interest statement
Figures





Similar articles
-
Potential Role of Nonneutralizing IgA Antibodies in Cross-Protective Immunity against Influenza A Viruses of Multiple Hemagglutinin Subtypes.J Virol. 2020 Jun 1;94(12):e00408-20. doi: 10.1128/JVI.00408-20. Print 2020 Jun 1. J Virol. 2020. PMID: 32269119 Free PMC article.
-
Heterosubtypic antiviral activity of hemagglutinin-specific antibodies induced by intranasal immunization with inactivated influenza viruses in mice.PLoS One. 2013 Aug 16;8(8):e71534. doi: 10.1371/journal.pone.0071534. eCollection 2013. PLoS One. 2013. PMID: 23977065 Free PMC article.
-
Cross-protective potential of a novel monoclonal antibody directed against antigenic site B of the hemagglutinin of influenza A viruses.PLoS Pathog. 2009 Mar;5(3):e1000350. doi: 10.1371/journal.ppat.1000350. Epub 2009 Mar 20. PLoS Pathog. 2009. PMID: 19300497 Free PMC article.
-
Intranasal Inactivated Influenza Vaccines: a Reasonable Approach to Improve the Efficacy of Influenza Vaccine?Jpn J Infect Dis. 2016;69(3):165-79. doi: 10.7883/yoken.JJID.2015.560. Jpn J Infect Dis. 2016. PMID: 27212584 Review.
-
Defense mechanisms against influenza virus infection in the respiratory tract mucosa.Jpn J Infect Dis. 2004 Dec;57(6):236-47. Jpn J Infect Dis. 2004. PMID: 15623947 Review.
Cited by
-
Extra-Neutralizing FcR-Mediated Antibody Functions for a Universal Influenza Vaccine.Front Immunol. 2019 Mar 18;10:440. doi: 10.3389/fimmu.2019.00440. eCollection 2019. Front Immunol. 2019. PMID: 30949165 Free PMC article. Review.
-
Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants.Front Immunol. 2022 Sep 12;13:995412. doi: 10.3389/fimmu.2022.995412. eCollection 2022. Front Immunol. 2022. PMID: 36172366 Free PMC article.
-
Impact of sex on humoral immunity with live influenza B virus vaccines in mice.NPJ Vaccines. 2024 Feb 26;9(1):45. doi: 10.1038/s41541-024-00827-x. NPJ Vaccines. 2024. PMID: 38409236 Free PMC article.
-
Anti-Chikungunya Virus Monoclonal Antibody That Inhibits Viral Fusion and Release.J Virol. 2020 Sep 15;94(19):e00252-20. doi: 10.1128/JVI.00252-20. Print 2020 Sep 15. J Virol. 2020. PMID: 32699087 Free PMC article.
-
Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones.J Virol. 2015 Apr;89(7):3610-8. doi: 10.1128/JVI.03099-14. Epub 2015 Jan 14. J Virol. 2015. PMID: 25589655 Free PMC article.
References
-
- Lamm ME (1997) Interaction of antigens and antibodies at mucosal surfaces. Annu Rev Microbiol 51: 311–340. - PubMed
-
- Murphy K, Travers P, Walport M, Janeway C (2008) Janeway's immunobiology. New York: Garland Science. xxi, 887 p.p.
-
- Corthesy B, Kraehenbuhl JP (1999) Antibody-mediated protection of mucosal surfaces. Curr Top Microbiol Immunol 236: 93–111. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous